Federal contract award
75A50124C00052
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEMONSTRATE THE VERSATILITY AND EFFICACY OF OUR PROGRAMMABLE ANTIVIRAL TECHNOLOGY PLATFORM BY ASSEMBLING THE PRECLINICAL PACKAGE FOR LNA14, PERFORMING A PHASE 1A STUDY IN HEALTHY ADULT HUMAN SUBJECTS, AND
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $52.5M |
| Current contract value | $52.5M |
| Potential contract value / ceiling | $351.6M |
| Start date | Sep 30, 2024 |
| Current end date | Mar 31, 2032 |
| Potential end date | Jun 30, 2032 |
| Latest award activity | Aug 21, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 5 of 5 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 21, 2026 | P00004 | $14.9M | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE ARTICLE B.3 ESTIMATED COST-PLUS FIXED FEE CLINS, ESTABLISH CLINS 3A (OPTION PERIOD 2A) AND CLIN 3B (OPTION PERIOD 2B), EXERCISE OPTION 3A, AND UPDATE SECTION J - LIST OF ATTACHMENTS, ATTACHMENT #1, STATEM |
| Sep 17, 2025 | P00003 | $3 | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE ARTICLE G.2 CONTRACTING OFFICER?S REPRESENTATIVE (COR) AND ADD FUNDS REGARDING REQUISITION ASP338221 IN THE AMOUNT OF $2.86 WHICH IS A CORRECTION TO P00001 FOR FUNDING TOTALS ALREADY CONTRACTUALLY AVAILAB |
| Mar 18, 2025 | P00002 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO 1) UPDATE ARTICLE G.2 CONTRACTING OFFICER'S REPRESENTATIVE (COR), 2) UPDATE ARTICLE G.5 CONTRACT FINANCIAL REPORT, AND 3) UPDATE ARTICLE I.1 FEDERAL ACQUISITION REGULATIONS (FAR) (48 CFR CHAPTER 1) CLAUSES |
| Jan 17, 2025 | P00001 | $17.0M | THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO EXERCISE OPTION 1 CLIN 0002 TO CONDUCT NON-CLINICAL STUDIES, 2ND NON-GLP TOX; EFFICACY/OFF-TARGET STUDIES AND UPDATE ARTICLE C.1. STATEMENT OF WORK DATED JANUARY 10, 2025. THE OPTION PERIOD OF PERFORMA |
| Sep 18, 2024 | 0 | $20.6M | THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEMONSTRATE THE VERSATILITY AND EFFICACY OF OUR PROGRAMMABLE ANTIVIRAL TECHNOLOGY PLATFORM BY ASSEMBLING THE PRECLINICAL PACKAGE FOR LNA14, PERFORMING A PHASE 1A STUDY IN HEALTHY ADULT HUMAN SUBJECTS, AND |
Estimated positioning window
Jun 30, 2031 – Dec 30, 2031
Modeled likelihood: 50%. These are AcornBids estimates, not confirmed solicitation dates.
{
"psc": "AN13",
"naics": "541714",
"agency": "Department of Health and Human Services",
"office": "BARDA - ASPR / DAAPPO / BARDA DCMA",
"incumbent": "4J THERAPEUTICS INC",
"known_forecast": false,
"option_end_date": "2032-06-30",
"contract_end_date": "2032-06-30",
"latest_action_date": "2026-08-21",
"modification_count": 5,
"previous_solicitation": "BAA-23-100-SOL-00004",
"historical_award_count": 121,
"historical_cadence_days": 24
}Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| BARDA-BAA@hhs.gov | Contact | BARDA-BAA@hhs.gov | Source | Mar 20, 2026 |
| BARDA-BAA@hhs.gov | Contact | BARDA-BAA@hhs.gov | Source | Mar 19, 2026 |
| BARDA-BAA@hhs.gov | Contact | BARDA-BAA@hhs.gov | Source | May 29, 2025 |
| BARDA-BAA@hhs.gov | Contact | BARDA-BAA@hhs.gov | Source | Dec 18, 2024 |
| BARDA-BAA@hhs.gov | Contact | BARDA-BAA@hhs.gov | Source | May 31, 2024 |
| BARDA-BAA@hhs.gov | Contact | BARDA-BAA@hhs.gov | Source | Apr 23, 2024 |
| BARDA-BAA@hhs.gov | Contact | BARDA-BAA@hhs.gov | Source | Mar 29, 2024 |
| BARDA-BAA@hhs.gov | Contact | BARDA-BAA@hhs.gov | Source | Dec 22, 2023 |
| BARDA-BAA@hhs.gov | Contact | BARDA-BAA@hhs.gov | Source | Nov 9, 2023 |
| BARDA-BAA@hhs.gov | Contact | BARDA-BAA@hhs.gov | Source | Sep 26, 2023 |
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.